Imugene’s $20 million boost and cancer trial updates

(7:42)

Imugene thrilled as first patient dosed in Phase 1 OASIS trial

(2:30)

Imugene’s $20 million boost and cancer trial updates

(7:42)

Imugene thrilled as first patients dosed in VAXINIA MAST combination study

(5:15)

Imugene thrilled with ethics approval for phase 2 HER-Vaxx trial

(4:45)

Groundbreaking cancer trial: Imugene’s CF33 advances in clinical success

(16:2)

Imugene thrilled as VAXINIA granted FDA Fast Track designation

(4:30)

Developing Cancer Cures through the ASX | Going Public w Leslie Chong \u0026 Paul Hopper

(53:26)

Groundbreaking cancer trial: Imugene’s CF33 advances in clinical success

(16:2)

Cramer: This biotech stock could be worth over $100 billion on an FDA approval

(5:19)

Imugene Investor Presentation | Non-deal Roadshow 2023 Australia

(44:28)

A Californian Cancer Killer Professor Yuman Fong and his work with Imugene

(26:16)

Interview With The CF33 Oncolytic Virus Inventor - Imugene (IMU)

(20:11)

Imugene Investor Webinar: MAST Study Update

(27:13)

Investor webinar: Azer-cel trial update, September 2024

(25:35)

Imugene's Science Series featuring the Oncolytic Viraltherapy CHECKvacc

(30:2)

Imugene welcomes positive FDA feedback on new manufacturing process for azer-cel

(4:10)

Imugene delighted as first cohort 3 patient dosed in CHECKvacc trial

(4:45)

Imugene thrilled as first patient dosed in Phase 1 OASIS trial

(2:30)

Imugene forges development path of immunotherapies and cancer-killing virus

(24:2)

Imugene's Leslie Chong thrilled with two significant FDA IND approvals

(4:45)

CAR T Explained

(3:58)

First Patient dosed in Imugene's PD1-Vaxx Combination Trial

(4:)

Changing the lives of cancer patients | Dr Leslie Chong of Imugene | ASX CEO Connect Series

(29:22)

Imugene's HER-Vaxx Immunotherapy Treatment: Explained

(3:15)

Imugene's Science Series: PD1-Vaxx (intro)

(37)

Imugene's CEO interviewed on ausbiz detailing a clinical trial deal with Merck Germany and Pfizer.

(4:12)